Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...
Pharmaceutical Technology on MSN
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...
Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback